Navigation Links
Pulmo BioTech Inc. Completes Bio-Distribution Studies
Date:7/7/2008

NEW YORK, July 7 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO.OB) has announced that its subsidiary, PulmoScience Inc. has completed the bio-distribution studies on its DFH-12 product candidate for the PulmoBind technology of Molecular Imaging of the vascular system of the lungs.

Molecular Imaging uses a molecule designed to bond specifically to certain parts of the body. In the case of PulmoBind, the chosen molecule was designed to bond only to the inner walls of the vascular system of the lungs. Because the molecule (code named DFH-12) is tagged with a radionuclide, the integrity of the lung's vascular system can then be imaged using the Gamma Cameras which are typically available in all hospitals with a Nuclear Medicine department.

It is important for diagnostic image quality that the PulmoBind molecule is only retained in the lungs, and we are very pleased to announce that in- vivo studies have shown that the molecule is predominantly retained in the lungs 30 minutes after injection with only minor retention (~ 1/10th) in the liver and heart. It is equally important that after imaging the molecule is quickly eliminated from the body and further bio-distribution studies have show that after 240 minutes the majority of the injected molecules have been eliminated through the kidneys and bladder.

About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stock holders.

About PulmoScience Inc.

PulmoScience Inc. was esta
'/>"/>

SOURCE Pulmo BioTech Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Tracleer(R) Shows Clinical Benefit as Combination Therapy with Sildenafil for Pulmonary Arterial Hypertension
2. Results of TRIUMPH-1 Trial of Viveta in Pulmonary Arterial Hypertension to Be Announced Before Market Open on Thursday, November 1, 2007
3. Study Shows Need to Test More COPD and Asthma Patients for Underdiagnosed Pulmonary Disease
4. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
5. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
6. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
7. Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
8. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
9. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
10. Positive Mid-Term Results on CryoValve(R) SG Pulmonary Human Heart Valve Presented at Western Thoracic Meeting
11. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)...- Stimulated by the ten years of Synapse® bus...SA announced today, at the Radiological Society of...n of its Medical Informatics Division . Formerly...tegrate all functions associated with the company,...future growth. ,, Several organizational change...
(Date:11/29/2009)...- Researchers using functional magnetic resonance ...d that men and women respond differently to positi...ented today at the annual meeting of the Radiologi...y direct more attention to sensory aspects of emot... implications for required action, whereas women d...
(Date:11/27/2009)... illnesses caused by subtypes A and B influenza vi...e-USNewswire/ -- The U.S. Food and Drug Administra...rs and older to prevent disease caused by influenz...ww.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) ,...Diagnostics in Siena, Italy, was approved using th...
Breaking Medicine Technology:FUJIFILM Establishes Medical Informatics Organization 2FUJIFILM Establishes Medical Informatics Organization 3New Study Finds Men and Women May Respond Differently to Danger 2New Study Finds Men and Women May Respond Differently to Danger 3FDA Approves Agriflu Seasonal Influenza Vaccine 2Parameter Generation and Control Launches New Catalog 26quot 3BPharmaceutical Stability Solutions 26quot 3B 14328 1Parameter Generation and Control Launches New Catalog 26quot 3BPharmaceutical Stability Solutions 26quot 3B 14328 2Case Managers 26apos 3B Role in Patient Care Offers Opportunity to Reduce Costs for Hospitals Providers 58737 1Case Managers 26apos 3B Role in Patient Care Offers Opportunity to Reduce Costs for Hospitals Providers 58737 2MedShare and Qualicode Bring BlackBerry Mobile EMR to Quebec 58732 1MedShare and Qualicode Bring BlackBerry Mobile EMR to Quebec 58732 2MedShare and Qualicode Bring BlackBerry Mobile EMR to Quebec 58732 3
...H SAN FRANCISCO, Calif., Feb. 15 Cell,Genesys, In...n analysis,examining the potential association bet...ostate cancer and increased patient survival in a ... refractory prostate cancer,(HRPC). More than 400 ...ere,identified in the sera of the treated patients...
...OURNE, Australia, Feb. 15 In a landmark study,ele...l of Respiratory and,Critical Care Medicine, a blo...TB Gold (QFT(TM)), has been shown to be six times ...n test (TST) at predicting,which tuberculosis (TB)...ase. This study has important implications for the...
Other Medicine Technology:Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer 2Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer 3Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer 4Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer 5Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control 2Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control 3Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control 4
(Date:11/29/2009)...s to teach doctors-in-training how to do ultrasoun... their skills without compromising patient care an... Hospital. , The study shows that this simulatio...improve medical residents, knowledge, dexterity an...n ultrasound-guided procedures, including breast b...
(Date:11/29/2009)...d of treatment equals a $41,000 pay raise, researc...y News) -- Psychological therapy may be much more ...ise or winning a lottery prize, suggests an Englis...ds of people who provided information about their ...appiness from a $1,329 course of therapy was so si...
(Date:11/28/2009)...8 Welcome to syngo® .pl...ical routine from Siemens Healthcare. As the f... (PACS) from Siemens where 2D, 3D, and 4D readin... poised to change the way multimodality images are... at the 95th Scientific Assembly and Annual Meeti...
(Date:11/28/2009)...ft spirits, recognize signs of depression , ...ny seniors, the holiday season can trigger melanch...with health issues or worry about money problems, ... To help overcome the seasonal blues, the AGS Foun...vice: , Get out and socialize or invite family a...
(Date:11/27/2009)...PRNewswire-USNewswire/ -- Considered a highly risk...s ago, solid organ transplantation is now a life-s...nary men and women who gathered at the Winspear Op...her from medical centers around the world to celeb...plant Institute (BRTI), one of the pioneers of sol...
Breaking Medicine News(10 mins):Health News:Simulated training for ultrasound-guided procedures improves safety without risk to patients 2Health News:Psychotherapy Can Boost Happiness More Than Money: Study 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 3Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3
...ooking Light editor will lead landmark launch. Hea... magazine,s ethos., NEW YORK, April 2, 2008 Lisa...he largest health magazine launch in history,sched...an 15 years of health expertise to the magazine. S...
...ril 2, 2008 , What: PocketCPR(TM), an FDA-...escuer in the delivery of high-quality cardiopulmo... will be used to teach chest compressions a...ttp://www.newscom.com/cgi-bin/prnh/20080402/NEW076...
...ril 2, 2008 The American College of Physicians (AC...y organizations, is participating in National Heal...initiative encourages all adults with decision-mak...es in a living will, and for providers and facilit...
...l 2, 2008 Mrs. Jane M. Knight, of,Hampton, Virgin...o,Worldwide Edition for her outstanding contributi... (Photo: http://www.newscom.com/cgi-bin/prnh/2008.... She was Nurse-Midwife with the,USAF Regional Hos...
..., April 2, 2008 ReBuilder,Medical Technologies, I...e,art electronic devices for diabetic peripheral n...reported March sales numbers exceeding all,previou...curve. We expect to continue that growth during th...
...il 2, 2008 /Xinhua-PRNewswire-FirstCall/ -- China,... ) ("China Shenghuo" or,"the Company"), which is e...nd marketing of pharmaceutical, nutritional supple...ainland China,Investor Tour to be held at Grand Hy...
Other Medicine News:Health News:Spry Names Lisa Delaney Editor in Chief 2Health News:State of Arizona to Use PocketCPR for Training Initiative on Hands-Only CPR 2Health News:Jane M. Knight Recognized By Strathmore's Who's Who Worldwide Publication 2Health News:ReBuilder Medical Technologies, Inc. Announces Top Sales Month - $410,000 2Health News:China Shenghuo Pharmaceutical Holdings, Inc. to Present at Brean Murray Carret & Co. Mainland China Investor Tour 2
... Xtra, and Maximum ACT introducers represent the l...ntroducers in the world. They are recognized as th...entional cardiology and electrophysiology procedur...therectomy, temporary pacing, endomyocardial biops...
Preface Braided Guiding Sheath
... Xtra, and Maximum ACT introducers represent the l...ntroducers in the world. They are recognized as th...entional cardiology and electrophysiology procedur...therectomy, temporary pacing, endomyocardial biops...
Bx Velocity Rx with Hepacoat
Medicine Products: